查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954192

抗生素抗藥性市場分析及預測（至2035年）：類型、產品、服務、技術、應用、最終用戶、流程、組件、設備、解決方案

Antibiotic Resistance Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Component, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 399 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，抗生素抗藥性市場規模將從2024年的109億美元成長至218億美元，年複合成長率約為8.2%。該市場涵蓋了為應對細菌抗生素抗藥性而開發的診斷、治療方法和預防措施。推動該行業發展的動力源於對抗多重抗藥性菌株和確保有效治療方法的迫切需求。主要趨勢包括對新型抗生素、快速診斷工具和全球抗生素管理計畫的投資。不斷提高的醫療保健意識和監管支持進一步推動了市場成長，為創新和合作應對這一重大公共衛生挑戰提供了重要機會。

受新型治療方法和診斷工具的迫切需求驅動，抗生素抗藥性市場正經歷強勁成長。就治療領域而言，BETA-內醯胺類和BETA-內醯胺酶抑制劑類藥物因其對抗藥性菌的有效性而表現最佳。醣肽已成為第二大細分市場，為多重抗藥性感染疾病提供了替代方案。診斷工具的重要性日益凸顯，其中快速診斷發揮主導作用，能夠快速識別抗藥性病原體。次世代定序（NGS）技術緊隨其後，提供全面的抗藥性分析。旨在發現新型抗生素和抗抗藥性藥物的研發投入不斷增加，進一步推動了市場發展。公私合營促進了創新，監管機構也支持加速核准流程。對抗生素管理計畫（ASP）的日益重視凸顯了永續使用抗生素的必要性，並為提供管理解決方案的公司創造了機會。隨著抗生素抗藥性威脅的日益加劇，策略夥伴關係和創新解決方案對於塑造未來至關重要。

市場區隔
類型 抗生素、抗病毒藥物、抗黴菌藥、抗寄生蟲藥
產品 藥品、診斷試劑、疫苗
服務 諮詢、檢驗和監測
科技 基因體學、蛋白質體學、生物資訊學、奈米技術
應用領域 人類醫學、獸醫學、農業
最終用戶 醫院、診所、研究機構、製藥公司
流程 藥物研發、藥物生產、品管
成分 原料藥、輔料
醫療設備 實驗室設備、照護現場設備
解決方案 感染控制，合理使用抗生素

抗生素抗藥性市場正經歷市場佔有率、定價和新產品發布方面的動態變化。主要產業參與者正透過創新應對日益嚴峻的抗藥性挑戰，從而形成具有競爭力的定價策略和尖端產品。頻譜抗生素的研發和個人化醫療方法正日益受到關注。這一市場演變是由不斷成長的醫療保健需求和對有效治療方法的迫切需求所驅動的。競爭基準研究表明，該市場由少數幾家大型製藥企業主導，但新興生物技術公司正在迅速崛起。監管因素，尤其是在北美和歐洲，正透過嚴格的核准流程和研發獎勵影響市場動態。這些法規在確保安全性和有效性的同時，也促進了創新。策略聯盟和併購是該市場的一個顯著特徵，有助於增強競爭優勢。全球對有效抗生素解決方案的需求持續成長，為致力於對抗抗生素抗藥性的相關人員提供了盈利的機會。

主要趨勢和促進因素：

抗菌藥物抗藥性市場正經歷顯著成長，這主要得益於人們對抗菌藥物抗藥性（AMR）作為全球健康威脅的認知不斷提高。關鍵趨勢包括新型抗生素和替代療法的研發投入不斷增加。各國政府和衛生組織正將抗菌藥物抗藥性應對計畫列為優先事項，並加強合作以對抗抗藥性。快速診斷技術的進步使得早期識別抗藥性菌株成為可能，從而改善治療效果並減少不合理使用抗生素。我們也看到，旨在加速藥物發現和開發的公私合營激增。不斷完善的法規結構正在簡化新抗菌藥物的核准流程，並促進創新。新興市場感染疾病負擔沉重，醫療基礎設施不斷完善，這些市場蘊藏著許多機會。專注於開發價格合理且易於獲取的解決方案的公司，將佔據有利地位，從而獲得可觀的市場佔有率。此外，人工智慧在藥物發現過程中的應用可望透過提高新抗生素開發的效率和效果，進一步改變市場格局。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
    • 抗寄生蟲藥物
    • 其他
  • 市場規模及預測：依產品分類
    • 製藥
    • 診斷
    • 疫苗
    • 其他
  • 市場規模及預測：依服務分類
    • 諮詢
    • 檢查室檢測
    • 監測
    • 其他
  • 市場規模及預測：依技術分類
    • 基因組學
    • 蛋白質體學
    • 生物資訊學
    • 奈米科技
    • 其他
  • 市場規模及預測：依應用領域分類
    • 人類藥物
    • 動物醫藥
    • 農業
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 製藥公司
    • 其他
  • 市場規模及預測：依製程分類
    • 藥物研發
    • 製藥生產
    • 品管
    • 其他
  • 市場規模及預測：依組件分類
    • 原料藥
    • 添加劑
    • 其他
  • 市場規模及預測：依設備分類
    • 實驗室設備
    • 照護現場設備
    • 其他
  • 市場規模及預測：按解決方案分類
    • 感染控制
    • 合理使用抗生素
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Melinta Therapeutics
  • Nabriva Therapeutics
  • Paratek Pharmaceuticals
  • Iterum Therapeutics
  • Motif Bio
  • Spero Therapeutics
  • Entasis Therapeutics
  • Achaogen
  • Venatorx Pharmaceuticals
  • Qpex Biopharma
  • Forge Therapeutics
  • Bugworks Research
  • Nosopharm
  • Bioversys
  • Debiopharm
  • Antabio
  • Acurx Pharmaceuticals
  • Aridis Pharmaceuticals
  • Macrolide Pharmaceuticals
  • Allecra Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS25770

Antibiotic Resistance Market is anticipated to expand from $10.9 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 8.2%. The Antibiotic Resistance Market encompasses the development and distribution of diagnostics, therapeutics, and preventive measures addressing bacterial resistance to antibiotics. This sector is driven by the urgent need to combat multidrug-resistant strains and ensure effective treatments. Key trends include investments in novel antibiotics, rapid diagnostic tools, and global stewardship programs. Rising healthcare awareness and regulatory support further propel market growth, offering substantial opportunities for innovation and collaboration in addressing this critical public health challenge.

The Antibiotic Resistance Market is experiencing robust growth, fueled by the urgent need for novel treatments and diagnostic tools. Within the therapeutic segment, the beta-lactam and beta-lactamase inhibitors sub-segment is the top-performing, driven by its effectiveness against resistant strains. Glycopeptides emerge as the second highest-performing sub-segment, offering alternatives for multi-drug resistant infections. Diagnostic tools are gaining prominence, with rapid diagnostics leading the charge, enabling timely identification of resistant pathogens. Next-generation sequencing (NGS) technologies follow closely, providing comprehensive resistance profiling. The market is further bolstered by increasing investments in research and development, aimed at discovering new antibiotics and resistance breakers. Public-private partnerships are enhancing innovation, while regulatory support accelerates approval processes. The growing emphasis on antimicrobial stewardship programs underscores the need for sustainable antibiotic use, creating opportunities for companies offering stewardship solutions. As the threat of antibiotic resistance intensifies, strategic collaborations and innovative solutions will be pivotal in shaping the market's future trajectory.

Market Segmentation
TypeAntibiotics, Antivirals, Antifungals, Antiparasitics
ProductDrugs, Diagnostics, Vaccines
ServicesConsulting, Laboratory Testing, Surveillance
TechnologyGenomics, Proteomics, Bioinformatics, Nanotechnology
ApplicationHuman Medicine, Veterinary Medicine, Agriculture
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies
ProcessDrug Development, Drug Manufacturing, Quality Control
ComponentActive Pharmaceutical Ingredients, Excipients
DeviceLaboratory Instruments, Point-of-Care Devices
SolutionsInfection Control, Antimicrobial Stewardship

The Antibiotic Resistance Market is witnessing a dynamic shift in market share, pricing, and new product launches. Key industry players are innovating to address the growing resistance challenges, resulting in competitive pricing strategies and cutting-edge product offerings. The focus is on developing broad-spectrum antibiotics and personalized medicine approaches. This market evolution is driven by increasing healthcare demands and a critical need for effective treatments. Competition benchmarking reveals a landscape dominated by a few major pharmaceutical companies, with emerging biotech firms gaining traction. Regulatory influences, particularly in North America and Europe, are shaping market dynamics by enforcing stringent approval processes and incentivizing research. These regulations drive innovation while ensuring safety and efficacy. The market is characterized by strategic partnerships and mergers, enhancing competitive positioning. The global demand for effective antibiotic solutions continues to rise, presenting lucrative opportunities for stakeholders committed to combating antibiotic resistance.

Geographical Overview:

The antibiotic resistance market is witnessing varied growth dynamics across regions, with distinct opportunities emerging. North America leads the market, driven by advanced healthcare infrastructure and significant investments in research to combat antibiotic resistance. The region's proactive measures and government initiatives are crucial in addressing this escalating concern. Europe follows with substantial investments in antibiotic stewardship programs and research initiatives. The European Union's stringent regulations and collaborative efforts among member states are fostering a robust market environment. Asia Pacific is a rapidly growing market, propelled by increasing awareness and rising healthcare expenditures. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure and research to tackle antibiotic resistance. Latin America and the Middle East & Africa are emerging as promising regions. In Latin America, countries like Brazil and Mexico are enhancing their healthcare systems, while in the Middle East & Africa, growing investments in healthcare are paving the way for market expansion.

Global tariffs and geopolitical tensions are significantly influencing the Antibiotic Resistance Market. In Japan and South Korea, strategic investments in biotech innovation and domestic pharmaceutical production are intensifying to mitigate import dependencies. China, facing international scrutiny and trade barriers, is bolstering its internal capabilities through robust R&D initiatives. Taiwan, while a pivotal player in pharmaceutical manufacturing, navigates geopolitical challenges by enhancing regional collaborations. The parent market is witnessing substantial growth driven by rising antimicrobial resistance awareness and government initiatives. By 2035, market evolution will hinge on technological advancements and cross-border partnerships. Concurrently, Middle East conflicts exert pressures on global supply chains and energy prices, indirectly affecting production costs and logistics in the pharmaceutical sector, thereby shaping strategic responses in these East Asian economies.

Key Trends and Drivers:

The antibiotic resistance market is experiencing pivotal growth driven by heightened awareness of antimicrobial resistance (AMR) as a global health threat. Key trends include increased research and development investments in novel antibiotics and alternative therapies. Governments and health organizations are prioritizing AMR action plans, fostering collaborations to combat resistance. Advancements in rapid diagnostic technologies are enabling quicker identification of resistant strains, thereby improving treatment outcomes and reducing inappropriate antibiotic use. The market is also witnessing a surge in public-private partnerships aimed at accelerating drug discovery and development. Regulatory frameworks are evolving to incentivize innovation and streamline approval processes for new antimicrobial agents. Opportunities abound in emerging markets where the burden of infectious diseases is high and healthcare infrastructure is expanding. Companies that focus on developing affordable and accessible solutions are well-positioned to capture significant market share. Additionally, the integration of artificial intelligence in drug discovery processes is expected to further revolutionize the market by enhancing the efficiency and effectiveness of new antibiotic development.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Device
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antibiotics
    • 4.1.2 Antivirals
    • 4.1.3 Antifungals
    • 4.1.4 Antiparasitics
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Diagnostics
    • 4.2.3 Vaccines
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Laboratory Testing
    • 4.3.3 Surveillance
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Bioinformatics
    • 4.4.4 Nanotechnology
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Human Medicine
    • 4.5.2 Veterinary Medicine
    • 4.5.3 Agriculture
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Drug Development
    • 4.7.2 Drug Manufacturing
    • 4.7.3 Quality Control
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Active Pharmaceutical Ingredients
    • 4.8.2 Excipients
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Laboratory Instruments
    • 4.9.2 Point-of-Care Devices
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Infection Control
    • 4.10.2 Antimicrobial Stewardship
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Device
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Device
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Device
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Device
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Device
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Device
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Device
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Device
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Device
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Device
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Device
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Device
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Device
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Device
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Device
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Device
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Device
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Device
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Device
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Device
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Device
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Device
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Device
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Device
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Melinta Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Nabriva Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Paratek Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Iterum Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Motif Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Spero Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Entasis Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Achaogen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Venatorx Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Qpex Biopharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Forge Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bugworks Research
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Nosopharm
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bioversys
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Debiopharm
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Antabio
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Acurx Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Aridis Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Macrolide Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Allecra Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us